Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.69 |
| ▸ | KLK1 | P06870 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485377 | 0.90 | KLKB1 (0.74) | KLKB1KLK1 | |
| SCHEMBL14485384 | 0.90 | KLKB1 (0.74) | KLKB1KLK1 | |
| SCHEMBL14486016 | 0.90 | KLKB1 (0.76) | KLKB1KLK1 | |
| SCHEMBL15901761 | 0.87 | KLKB1 (0.71) | KLKB1KLK1 | |
| SCHEMBL14485474 | 0.87 | KLKB1 (0.71) | KLKB1KLK1 | |
| SCHEMBL28886997 | 0.85 | KLKB1 (0.66) | KLKB1KLK1 | |
| SCHEMBL22344723 | 0.85 | KLKB1 (0.87) | KLKB1KLK1 | |
| SCHEMBL15901410 | 0.85 | KLKB1 (0.87) | KLKB1KLK1 | |
| SCHEMBL15901801 | 0.83 | KLKB1 (0.77) | KLKB1KLK1 | |
| SCHEMBL15902027 | 0.83 | KLKB1 (0.74) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| CN-111032018-A | Pharmaceutical composition | 卡尔维斯塔制药有限公司 | 2020-04-17 | — | — | CN | claimed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | claimed |
| US-10478409-B2 | Pharmaceutical compositions | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-11-19 | — | — | US | claimed |
| EP-2943181-B1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-04-10 | — | — | EP | claimed |
| US-20180021271-A1 | Pharmaceutical Compositions | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-01-25 | — | — | US | claimed |
| US-9849100-B2 | Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-26 | — | — | US | claimed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | claimed |
| US-20150342910-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | claimed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | claimed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | claimed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | claimed |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| CN-111032018-A | Pharmaceutical composition | 卡尔维斯塔制药有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342910-A1 | PHARMACEUTICAL COMPOSITIONS | PDE6D, ABCC9, RAB29 | KLKB1 2921/4885KLK1 2277/4885 |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | ADCY9, PDE6D, PDE6G | KLKB1 4010/4885KLK1 3047/4885 |
| US-20180021271-A1 | Pharmaceutical Compositions | PDE6D, ABCC9, PDE6H | KLKB1 2771/4885KLK1 2493/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885KLK1 2/4885 |
| US-10478409-B2 | Pharmaceutical compositions | PDE6D, ABCC9, PDE6H | KLKB1 2771/4885KLK1 2493/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885KLK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.